Dimensional Fund Advisors LP Purchases 47,795 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dimensional Fund Advisors LP grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 2.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,933,560 shares of the biopharmaceutical company's stock after purchasing an additional 47,795 shares during the period. Dimensional Fund Advisors LP owned about 1.52% of Halozyme Therapeutics worth $92,446,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth about $29,000. Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the last quarter. Venturi Wealth Management LLC bought a new stake in Halozyme Therapeutics during the fourth quarter worth about $69,000. Finally, Parkside Financial Bank & Trust lifted its stake in shares of Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 322 shares during the last quarter. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $60.57 on Tuesday. The stock has a market cap of $7.48 billion, a P/E ratio of 17.66, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The firm's fifty day simple moving average is $60.56 and its 200 day simple moving average is $55.20. Halozyme Therapeutics, Inc. has a twelve month low of $37.97 and a twelve month high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

HALO has been the subject of a number of recent research reports. Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. HC Wainwright reissued a "buy" rating and issued a $72.00 target price on shares of Halozyme Therapeutics in a research note on Friday. Finally, Piper Sandler boosted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.89.

Insider Activity

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,697 shares of company stock worth $1,558,052. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.